December round-up of pharma/biotech M&A activity

30 December 2016

The year's final month has brought with it some intriguing deals reflecting the diverse and global nature of pharma today.

Deals have involved not just the established big pharma players such as US giant Pfizer (NYSE: PFE) making a move in immuno-oncology, Switzerland's Novartis (NOVN: VX) snapping up dermatology and opthalmology assets and frequent dealmaker Allergan (NYSE: AGN) notching up its tenth acquisition of the year.

Among the other activity has been a Japanese company with a background in glass manufacturing strengthening its life science business, privately-held Israel-based Otic Pharma announcing a deal to create a company focused on ear, nose and throat disorders, and two US firms merging to advance their aspirin product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK